Helsinki Improved Transcranial magnetic stimulation vs treatment as usual for depression

Hospital District of Helsinki and Uusimaa0 sites80 target enrollmentStarted: June 1, 2021Last updated: January 8, 2024

Trial Snapshot

No summary available.

•1. Diagnosis of major depressive disorder (DSM-IV) as the principal diagnosis with Patient Health Questionnaire-9 score >14
•2. Inability to tolerate antidepressant medication or unresponsiveness to minimum of 2 months trial with adequate dose of antidepressant
•3. No change in antidepressive medication in four weeks prior to treatment

•1. Previous rTMS treatment
•2. Borderline personality features exceeding 7 points in McLean Screening Instrument for Borderline Personality Disorder, or other somatic or psychiatric conditions that likely interfere with recovery from depression with TMS (an unstable medical illness, substantial neurological illness, chronic pain, psychotic disorder or current psychotic symptoms, substance abuse or dependency within last 3 months, >2 mg lorazepine equivalents benzodiazepine use daily or any anticonvulsant, or lifetime history of non-response to an adequate course—ie, a minimum of eight treatments—of electroconvulsive therapy)
•3. Patients with safety risks including active suicidality, pregnancy, magnetic metal or leads in the upper body, or history of seizures

Sponsor

Hospital District of Helsinki and Uusimaa